Flex Pharma shareholders OK reverse-merger after drug failure
Shareholders have approved a plan making Flex Pharma, the neurobiology-focused biotech started five years ago by a Nobel Prize winner and one of the founders of Alnylam Pharmaceuticals Inc., into a shell company for a privately held Houston cancer drug developer.
Flex Pharma (Nasdaq: FLKS) was co-founded in 2014 by Nobel Prize Winner Rod MacKinnon and serial entrepreneur Christoph Westphal. The company began looking for a merger partner after its “tolerability concerns” arose during a mid-stage…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news
More News: Biotechnology | Brain | Cancer | Cancer & Oncology | Health Management | Mergers and Aquisitions | Neurology | Pharmaceuticals